17,261 trials
Rheumatoid Arthritis
Primary: Change in CRP From Baseline to Day 42 — -16.12; 9.60 percentage change from baseline
Non-Hodgkin's Lymphoma · Mantle Cell Lymphoma
Primary: Overall Response Rate — 40; 55; 29 percentage of patients
Head and Neck Neoplasms
Primary: Progression-Free Survival (PFS) — 5.1 months
Congenital Heart Disease · Hypoplastic Left Heart Syndrome · Transposition of the Great Arteries
Primary: Relative Difference in Total Maturity Score (TMS) From Preoperative Brain MRI to 7 Day Postoperative MRI — 12.1; 9.44 Percentage
Nausea and Vomiting
Primary: Vomiting at 0 to 120 Min. — 1; 4 number of participants exp vomiting
Alcohol Dependence · PTSD
Primary: Retrieval Session Distress Scores (Session 1) — 54.5; 73.9 units on a scale
Coronary Artery Disease
Primary: Extent of Preservation of Inhibitory Effect Compared With Effect Observed With Cangrelor Alone (at Timepoint 1, Either at 0.5 Hours or 1.25 Hours) or Ticagrelor Alone…
Medication Adherence
Primary: Self-efficacy - 8 Item Measure Taps Into Key Concepts Associated With Confidence for Managing Opioid Medications — 28.1081; 27.0563; 29.7143; 28.3224 units on a scale
Postoperative Pain
Primary: Total Morphine Consumption in the First 24 Hours Following Postoperative Study Drug Treatment — 21.9; 17.6; 13.9; 19.8 mg — p=<0.05
Influenza
Primary: Number of Participants Reporting Serious Adverse Events (SAEs) — 1; 0; 2; 1 participants
Prostatitis · Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Primary: Global Response Assessment — 2 participants
Hunter Syndrome
Primary: Number of Serious Adverse Event (SAE) — 0; 8; 3; 3 events
Breast Cancer
Primary: Progression Free Survival — 103; 81 Days
Diabetes Mellitus, Type 2
Primary: Glucagon Concentration (Nanomoles Per Liter [Nmol/L]) During the Hypoglycemic Periods of the Glucose Clamp Procedure — 0.03780; 0.03805; 0.03780; 0.03780 Nanomoles per…
Meningioma
Primary: 6 Month Progression Free Survival — 11; 44 percentage of patients